Skip to main content
Terug
Watch Compare

EXAGEN INC.

Datakwaliteit: 100%
XGN
NASDAQ Services Health Services
€ 3,03
▼ € 0,06 (-1,94%)
Marktkapitalisatie: 74,32 M
Prijs
€ 3,09
Marktkapitalisatie
74,32 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 8,35% annually over 5 years — modest growth
Negative free cash flow of -14,27 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11,30%
Capital efficient — spends only 0,96% of revenue on capex

Groei

Revenue Growth (5Y)
8,35%
Boven sectorgemiddelde (3,76%)
Revenue (1Y)19,65%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-101,86%
Onder sectorgemiddelde (-15,99%)
ROIC-22,59%
Net Margin-29,97%
Op. Margin-21,13%

Veiligheid

Debt / Equity
1,26
Boven sectorgemiddelde (0,39)
Current Ratio4,08
Interest Coverage-3,26

Waardering

PE (TTM|NTM)
-3,73 | -9,77
Onder sectorgemiddelde (-1,19)
P/B Ratio4,10
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (515 peers)
Metriek Aandeel Sector Mediaan
P/E -3,7 -1,2
P/B 4,1 1,4
ROE % -101,9 -16,0
Net Margin % -30,0 -19,4
Rev Growth 5Y % 8,4 3,8
D/E 1,3 0,4

Koersdoel Analisten

6 analisten
Buy
Huidig
€ 3,03
+213.5%
Koersdoel
€ 9,50
€ 8,00
€ 10,00
€ 10,00
Vooruitzicht
Forward K/W -9,77
Forward WPA -€ 0,31
Omzet Sch. 79,74 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,31
-€ 0,49 – -€ 0,13
 79,74 M 2
FY2026 -€ 0,80
-€ 0,80 – -€ 0,80
 71,07 M 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,19 -€ 0,27 -37,7%
Q32025 -€ 0,16 -€ 0,31 -96,8%
Q22025 -€ 0,15 -€ 0,18 -18,8%
Q12025 -€ 0,21 -€ 0,20 +3,2%

ETFs Holding This Stock

BRUSX BRUSX
0,30% weight
BRSIX BRSIX
0,07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 19,65% Revenue Growth (3Y) 12,56%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,35% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 66,58 M Net Income (TTM) -19,95 M
ROE -101,86% ROA -32,82%
Gross Margin 58,28% Operating Margin -21,13%
Net Margin -29,97% Free Cash Flow (TTM) -14,27 M
ROIC -22,59% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,26 Current Ratio 4,08
Interest Coverage -3,26 Asset Turnover 1,10
Working Capital 39,70 M Tangible Book Value 18,14 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,73 Forward P/E -9,77
P/B Ratio 4,10 P/S Ratio 1,12
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0,93 Fwd Earnings Yield N/A
FCF Yield -19,19%
Market Cap 74,32 M Enterprise Value 61,61 M
Per Share
EPS (Diluted TTM) -0,93 Revenue / Share 2,77
FCF / Share -0,59 OCF / Share -0,57
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,96% FCF Conversion 71,51%
SBC-Adj. FCF -15,94 M Growth Momentum 11,30

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 66,58 M 55,64 M 52,55 M 45,56 M 48,30 M
Net Income -19,95 M -15,12 M -23,69 M -47,39 M -26,85 M
EPS (Diluted) -0,93 -0,83 -1,34 -2,77 -1,68
Gross Profit 38,80 M 33,11 M — — —
Operating Income -14,07 M -13,64 M -22,84 M -46,05 M -24,07 M
EBITDA — — — — —
R&D Expenses 6,25 M 5,38 M 4,87 M 9,88 M 7,24 M
SG&A Expenses 46,62 M 41,37 M 47,43 M 52,02 M 44,54 M
D&A 2,10 M 1,70 M 2,20 M 1,60 M 900.000,0
Interest Expense 4,32 M 2,23 M 2,34 M 2,45 M 2,63 M
Income Tax 51.000,0 12.000,0 33.000,0 -282.000,0 175.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 58,02 M 44,69 M 56,94 M 86,22 M 123,45 M
Total Liabilities 40,57 M 35,15 M 34,25 M 43,76 M 38,51 M
Shareholders' Equity 17,45 M 9,54 M 22,69 M 42,46 M 84,94 M
Total Debt 22,91 M 20,25 M 19,50 M 28,97 M 27,48 M
Cash & Equivalents 32,22 M 22,04 M 36,49 M 62,39 M 99,44 M
Current Assets 48,89 M 36,46 M 47,84 M 72,61 M 112,73 M
Current Liabilities 14,16 M 13,51 M 11,90 M 9,62 M 9,32 M